Maternal Sirolimus Therapy for Fetal Extensive Lymphatic Cystic Malformation: Selection Criteria, Management, and Outcomes in a Series of Six Cases
What this study shows
Maternal rapamycin (sirolimus) therapy for extensive fetal lymphatic malformations. Prenatal mTOR inhibition feasible with partial/marked lesion regression in 5/6 newborns; transplacental transfer observed. Observational case series (n=6); confounding by indication not excluded.
At a glance
| Evidence type | H Human study Marked H because it is direct evidence from a human clinical trial or human cohort; the code names the kind of study, not its quality -- a small, well-run trial is still H. |
| Study type | 3 - Human Observational |
| Model system | — |
| Journal | Prenatal Diagnosis |
| Year | 2026 |
| Peer reviewed | Yes |
| Record last updated | 2026-08-22 |
| Source | DOI 10.1002/pd.70230 · PMID 42607031 |